Lavipharm S.A
Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; and over the counter (OTC) drugs,… Read more
Lavipharm S.A (LAVI) - Total Liabilities
Latest total liabilities as of December 2024: €72.52 Million EUR
Based on the latest financial reports, Lavipharm S.A (LAVI) has total liabilities worth €72.52 Million EUR as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lavipharm S.A - Total Liabilities Trend (2014–2024)
This chart illustrates how Lavipharm S.A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lavipharm S.A Competitors by Total Liabilities
The table below lists competitors of Lavipharm S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Savannah Resources Plc
PINK:SAVNF
|
USA | $3.81 Million |
|
GFLT
PINK:GFLT
|
USA | $570.27K |
|
Kirloskar Industries Limited
NSE:KIRLOSIND
|
India | ₹35.24 Billion |
|
Pacific Edge Ltd
AU:PEB
|
Australia | AU$7.71 Million |
|
Fu Chun Shin Machinery Manufacture Co Ltd
TWO:6603
|
Taiwan | NT$5.72 Billion |
|
Kudelski S.A.
LSE:0QNQ
|
UK | £228.06 Million |
|
Renalytix Plc
OTCQB:RNLXY
|
USA | $12.81 Million |
|
Cango Inc
NYSE:CANG
|
USA | $4.62 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Lavipharm S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lavipharm S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lavipharm S.A (2014–2024)
The table below shows the annual total liabilities of Lavipharm S.A from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €72.52 Million | +0.70% |
| 2023-12-31 | €72.02 Million | -2.54% |
| 2022-12-31 | €73.89 Million | +17.89% |
| 2021-12-31 | €62.68 Million | -0.42% |
| 2020-12-31 | €62.94 Million | -1.38% |
| 2019-12-31 | €63.82 Million | +3.90% |
| 2018-12-31 | €61.43 Million | -5.10% |
| 2017-12-31 | €64.73 Million | -19.09% |
| 2016-12-31 | €80.00 Million | -45.50% |
| 2015-12-31 | €146.80 Million | +10.55% |
| 2014-12-31 | €132.79 Million | -- |